PDCD1 and melanoma: Pembrolizumab, another PD-1 inhibitor, has been approved for cervical cancer, gastric cancer, HNSCC, HCC, cHL, melanoma, MCC, NSCLC, diffuse large B-cell lymphoma (DLBCL), and urothelial cancer.